NP prescribing authority by state: what you can prescribe and where

What an NP can prescribe depends almost entirely on which state they practice in. The variation is significant: in one state an NP can independently prescribe Schedule II controlled substances with no physician involvement; in another, a co-signing physician must review and countersign every prescription. For NPs considering relocation, evaluating these differences before accepting a job offer is essential.

This guide explains the three practice authority frameworks, what each means for prescribing in practice, and how to verify your specific state’s current rules.

The three practice authority frameworks

The NCSBN APRN Consensus Model defines three broad categories of NP practice environment. These aren’t just about prescribing – they govern the entire scope of NP practice – but prescribing is where the day-to-day difference is most visible.

Full practice authority (FPA) The NP can evaluate, diagnose, interpret diagnostics, and initiate treatment – including prescribing – without required physician involvement. No collaborative practice agreement (CPA) required. The NP practices to the full extent of their education and national certification.

As of the AANP State Practice Environment map (May 2026 revision), 27 states and the District of Columbia have granted full practice authority to NPs, including most Western states, most Northeastern states, and a growing number of Midwestern states. The list continues to expand as state legislatures act.

Reduced/collaborative practice The NP must maintain a collaborative practice agreement (CPA) with a supervising or collaborating physician. The terms of what the physician must review or co-sign vary by state. Some states require only a written agreement with periodic chart review; others require active physician co-signature on prescriptions or specific chart review percentages.

Restricted practice The NP must work under direct physician supervision for some or all practice activities. Prescribing may require physician co-signature or counter-signature within a defined time window. These states represent the most constrained NP practice environments.

Controlled substances: the DEA layer on top of state law

Even in full-practice-authority states, NPs must comply with federal DEA requirements to prescribe controlled substances. Obtaining a DEA registration is an independent process separate from state licensure – you apply directly to the DEA and are issued a DEA number tied to your specific practice location.

Most states that have granted FPA also allow NPs with a DEA registration to prescribe Schedule II–V controlled substances independently. However, some states have carved out additional restrictions even within FPA frameworks:

• A small number of FPA states still require a collaborative agreement specifically for Schedule II prescribing
• Some states require additional state-level registration (separate from DEA) to prescribe certain drug classes
• State Prescription Drug Monitoring Programs (PDMPs) have NP-specific enrollment and reporting requirements that vary

This means even in a technically “full practice authority” state, an NP may face additional steps before prescribing opioids, stimulants, or benzodiazepines.

State summary: practice authority and CDS prescribing

The table below groups states by practice authority level and notes controlled substance prescribing capacity. This is a summary for orientation purposes – rules change frequently and specific restrictions vary. Always verify current rules with your state board of nursing and the AANP’s State Practice Environment resource before making any practice or relocation decision.

Sources: AANP State Practice Environment resource (aanp.org), individual state BON pages. This table reflects general frameworks as of mid-2026. Several states were actively considering FPA legislation at time of publication. Verify all entries with your state BON before making any practice decision.

What the practice authority level means day-to-day

The difference between FPA and restricted practice isn’t just paperwork. It shapes the clinical relationship and what you can prescribe in real time.

In an FPA state: You prescribe based on your own clinical judgment. You don’t wait for physician review before sending a prescription. You don’t pay a collaboration fee. For Schedule II prescriptions, you use your DEA number the same way a physician would.

In a reduced/collaborative state: The CPA defines what you can prescribe and under what conditions. The physician collaborator may need to review a percentage of charts monthly – some states require 10%, others 20%, some require site visits. Some CPAs prohibit Schedule II prescribing entirely or require physician counter-signature. The practical limits depend on what your specific CPA says, not just the state law.

In a restricted state: Some prescribing may require real-time or near-real-time physician involvement. In the most restrictive states, the physician must be physically present or immediately available for certain prescribing decisions.

How to verify your state’s current rules

State NP prescribing law changes regularly. A state that was reduced in 2023 may have shifted to FPA in 2024. Don’t rely on a guide published more than a year ago.

The most current information is available at:

• Your state board of nursing – the primary legal authority. Many BONs publish detailed FAQ pages on NP scope of practice
• AANP State Practice Environment – maintained at aanp.org, updated regularly as state laws change
• NCSBN – publishes the APRN Consensus Model and maintains data on state implementation

When verifying, look specifically for:

• Whether FPA applies immediately upon licensure or requires a practice period (Connecticut requires a transition period of supervised practice before FPA kicks in)
• Whether your specialty certification (FNP, AGPCNP, NNP, etc.) affects scope
• Any additional state registration requirements for controlled substances beyond the federal DEA

Common misconceptions about NP prescribing

“FPA means I can prescribe anything a physician can.” Not without qualification. FPA removes the collaborative agreement requirement, but your scope of practice is still bounded by your specialty certification and education. An FNP cannot prescribe within a neonatal scope simply because FPA exists in their state.

“If the state has FPA, the DEA registration is automatic.” DEA registration is a separate federal application process. It takes weeks and requires a practice address. FPA does not grant or accelerate DEA registration.

“My CPA covers controlled substances by default.” CPAs vary enormously. Read yours before prescribing – many have explicit exclusions for Schedule II drugs or require separate physician authorization.

“Hospital privileges work the same way as state prescribing authority.” Hospitals credential independently. An FPA state doesn’t force hospitals to grant independent admitting or prescribing privileges – many still require physician attestation for NP credentialing. This is one of the most common surprises for NPs moving to FPA states.

Choosing a practice state: what to weigh beyond prescribing authority

If you’re evaluating states based on practice environment, prescribing authority is one factor among several:

• Supervision fees: In collaborative practice states, physicians can charge $1,000–$3,000/month for a CPA, or more for subspecialty collaboration. This directly affects the economics of independent practice.
• NP job market saturation: FPA states attract NPs, which increases competition for desirable positions and can suppress salaries.
• Reimbursement parity: Some states require payers to reimburse NPs at the same rate as physicians for the same service. Others allow insurers to pay NPs at 85% of physician rates, affecting practice revenue.
• Medicaid NP billing: Whether your state allows NPs to bill Medicaid directly as primary providers varies independently of FPA status.
• Patient panel rules: Some hospital systems and insurers cap NP panel sizes or require physician co-management above certain case complexity thresholds – regardless of what state law says.

For NPs comparing specific state combinations, see our guide on NP collaborative practice agreements. For DEA registration specifics, see NP DEA registration. For malpractice coverage considerations that vary by practice authority level, see NP malpractice insurance.

References

1. American Association of Nurse Practitioners, “State Practice Environment,” AANP, 2026. https://www.aanp.org/advocacy/state/state-practice-environment
2. National Council of State Boards of Nursing, “APRN Consensus Model: Report of the APRN Consensus Work Group and the NCSBN APRN Advisory Committee,” NCSBN, 2008. https://www.ncsbn.org/nursing-regulation/practice/aprn/aprn-consensus.page
3. U.S. Drug Enforcement Administration, “Registration: Mid-Level Practitioners Authorization by State,” DEA Diversion Control Division, 2024. https://www.deadiversion.usdoj.gov/drugreg/registration.html
4. U.S. Drug Enforcement Administration, “Controlled Substance Schedules,” DEA Diversion Control Division, 2024. https://www.deadiversion.usdoj.gov/schedules/
5. American Association of Nurse Practitioners, “State Practice Environment,” AANP. https://www.aanp.org/advocacy/state/state-practice-environment
6. National Conference of State Legislatures, “Scope of Practice Policy: Nurse Practitioner Practice and Prescriptive Authority,” NCSL, 2024. https://www.ncsl.org/scope-of-practice-policy/practitioners/advanced-practice-registered-nurses/nurse-practitioner-practice-and-prescriptive-authority
7. Centers for Disease Control and Prevention, “Prescription Drug Monitoring Programs (PDMPs),” CDC, 2024. https://www.cdc.gov/overdose-prevention/php/interventions/prescription-drug-monitoring-programs.html